Acusphere, Inc. ACUS

Company Overview

Acusphere, Inc. (NASDAQ: ACUS) was a U.S.-based pharmaceutical and medical imaging company focused on developing injectable imaging agents used in diagnostic ultrasound and other imaging applications. The company operated within the biotechnology, specialty pharmaceutical, and medical diagnostics industries, with its primary commercial focus centered on contrast agents designed to improve cardiovascular imaging quality. Its most prominent product candidate was Imagify, a perflubutane polymer microsphere injectable contrast agent intended to enhance ultrasound imaging for the detection of coronary artery disease.

The company was founded in 1993 and headquartered in Watertown, Massachusetts. Acusphere’s business model relied heavily on research and development activities and the advancement of proprietary imaging technologies through clinical trials and regulatory review. The company’s strategic positioning was based on the potential cost and safety advantages of ultrasound imaging compared with more invasive or radiation-based diagnostic procedures. Public filings and market records indicate that Acusphere faced significant financial and regulatory challenges following the U.S. Food and Drug Administration’s response to Imagify, ultimately leading to bankruptcy proceedings and the cessation of active operations. Data regarding any continuing operating activities after liquidation is inconclusive based on available public sources.